Oppenheimer Maintains Outperform on Ascendis Pharma, Raises Price Target to $312
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
Oppenheimer analyst Leland Gershell maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $304 to $312.
Oppenheimer analyst Leland Gershell maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $304 to $312.